Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Lordick F., Shah M. A., Shitara K., Ajani J. A., Bang Y., Enzinger P. C., ...Daha Fazla
ANNALS OF ONCOLOGY, 2023 (SCI-Expanded, Scopus)
-
Yayın Türü:
Makale / Özet
-
Basım Tarihi:
2023
-
Doi Numarası:
10.1016/j.annonc.2023.10.270
-
Dergi Adı:
ANNALS OF ONCOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
-
Bezmiâlem Vakıf Üniversitesi Adresli:
Evet